Neuronetics, Inc.
NASDAQ:STIMMedical - Diagnostics & Research
+$0.00 today
- Market cap
- $97.16M
- Beta
- 1.04
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.53
Volume 2.55M
Average 2.44M
STIM Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Neuronetics, Inc.NASDAQ: STIM
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns negative
Q1 FY2026 financing cash flow was -$5.58M, compared with $18.98M a year earlier. Trailing-twelve-month financing cash flow was $11.3M. Over 3 fiscal years it compounded at +457.4% a year.
Context
- Financing cash flow amounted to 24.0% of revenue in FY2025, up 14.9 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near -$5.58M or moves back toward the trailing-twelve-month quarterly average of $2.82M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 35.85M USD
- Year-over-year change
- +626.6%
- 4-year CAGR
- -18.9%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.85M | +626.6% |
| FY2024 | 2024-12-31 | (6.81M) | -130.0% |
| FY2023 | 2023-12-31 | 22.7M | +10864.7% |
| FY2022 | 2022-12-31 | 207K | -99.8% |
| FY2021 | 2021-12-31 | 83.01M | — |
Financing Cash Flow vs competitors
How STIM compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.2% is the 6th highest of 9, against a peer median of +23.7%.
- Financing cash flow amounts to 7.4% of revenue for STIM, versus a peer median of 96.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $164.7M USD | +23.8% | +468.8% | 26649.8% | |
| LTM Mar 2026 | $89.31M USD | +520.7% | -5.8% | 258.5% | |
| LTM Mar 2026 | $42.24M USD | +23.6% | +81.2% | 223.8% | |
| LTM Mar 2026 | €38.51M EUR | -50.0% | — | 236.0% | |
| LTM Mar 2026 | $27.87M USD | +110.1% | -36.8% | 96.4% | |
| LTM Mar 2026 | $26.83M USD | -17.0% | — | 34.4% | |
| LTM Mar 2026 | $24.27M USD | — | -36.0% | 21.3% | |
| LTM Mar 2026 | $22.27M USD | +481.2% | -83.6% | 19.7% | |
| LTM Mar 2026 | $11.3M USD | -7.2% | +457.4% | 7.4% | |
ATLNAtlantic International Corp. | LTM Dec 2025 | $3.87M USD | -28.2% | — | 0.9% |
| Peer median (excluding STIM) | — | +23.7% | -20.9% | 96.4% | |
Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (31.19M) | (37.16M) | (30.19M) | (43.73M) | (39.14M) |
| Depreciation & Amortization | 1.06M | 1.65M | 2.01M | 2.07M | 3.47M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.87M | 8.75M | 7.32M | 5.6M | 6.85M |
| Change in Working Capital | (6.64M) | (5.12M) | (14.1M) | (6.81M) | 6.58M |
| Accounts Receivables | (3.05M) | (6.66M) | (8.83M) | (3.73M) | 3.54M |
| Inventory | (3.44M) | (2.59M) | (1.1M) | 3.15M | (395K) |
| Accounts Payables | 276K | (1.97M) | 2.03M | (1.99M) | (1.75M) |
| Other Working Capital | (415K) | 6.1M | (6.2M) | (4.25M) | 5.18M |
| Other Non-Cash Items | 918K | 1.14M | 2.93M | 11.86M | 1.87M |
| Operating Cash Flow | (27.98M) | (30.74M) | (32.04M) | (31M) | (20.37M) |
| Capital Expenditures | (2.35M) | (3.27M) | (2.37M) | (1.47M) | (801K) |
| Acquisitions (Net) | 0 | 0 | 0 | (2.55M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 324K | 0 | 0 | 0 | (31K) |
| Other Investing Activities | (7.81M) | 10M | 1.05M | 1.61M | 31K |
| Investing Cash Flow | (9.84M) | 6.73M | (1.32M) | (2.41M) | (801K) |
| Debt Repayment | 0 | 0 | 23.8M | (2.52M) | 9.62M |
| Common Stock Issued | 80.97M | 0 | 0 | 0 | 26.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.03M | 207K | (1.1M) | (4.29M) | (594K) |
| Financing Cash Flow | 83.01M | 207K | 22.7M | (6.81M) | 35.85M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 45.18M | (23.8M) | (10.66M) | (40.22M) | 14.68M |
| Free Cash Flow | (30.34M) | (34.01M) | (34.41M) | (32.46M) | (21.18M) |
Neuronetics, Inc.
NASDAQ:STIM
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.